Regen BioPharma, Inc. (RGBP)
USD 0.07
(-16.47%)
USD 0.07
(-16.47%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -173.91 Thousand | -606.92 Thousand | -1.13 Million | 18.64 Thousand | -481.79 Thousand | -1.57 Million |
| Net Income | 1.15 Million | 2.44 Million | -6.76 Million | 3.41 Million | -2.62 Million | -4.71 Million |
| Depreciation & Amortization | 864.00 | 71.06 Thousand | 51.01 Thousand | 609.52 Thousand | 1.4 Million | 1.3 Million |
| Deferred income taxes | -255.14 Thousand | -45.5 Thousand | -51.01 Thousand | -3600.00 | -1.4 Million | - |
| Stock-based compensation | 348.37 Thousand | 45.5 Thousand | 1.00 | 3600.00 | 54.84 Thousand | 151.11 Thousand |
| Change in working capital | -1.92 Million | -3.13 Million | 4.45 Million | -4 Million | 639.85 Thousand | 1.27 Million |
| Other non-cash items | 503.99 Thousand | 15.89 Thousand | 1.18 Million | 3600.00 | 1.5 Million | 555.57 Thousand |
| Investing Cash Flow | - | 25 Thousand | 495 Thousand | - | 49.85 Thousand | -5741.00 |
| Investments in PPE | -3.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | 25 Thousand | 495 Thousand | - | 49.85 Thousand | - |
| Other Investing Activities | - | 25 Thousand | 495 Thousand | - | 49.85 Thousand | -5741.00 |
| Financing Cash Flow | 243.75 Thousand | -94.03 Thousand | 1.36 Million | -26.5 Thousand | 431.77 Thousand | 1.32 Million |
| Debt repayment | -243.75 Thousand | -94.53 Thousand | -1.36 Million | -26.5 Thousand | -431.56 Thousand | -1.38 Million |
| Dividends payments | - | - | - | - | - | -5741.00 |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 250 Thousand | 45.5 Thousand | 159.00 | 3000.00 | 5500.00 | 50 Thousand |
| Other Financing Activities | 237.5 Thousand | -45 Thousand | 2.72 Million | -3000.00 | 857.83 Thousand | -61.12 Thousand |
| Accounts receivables | 254.27 Thousand | -41.08 Thousand | -109.99 Thousand | -34.1 Thousand | -71.18 Thousand | 29.76 Thousand |
| Accounts payables | 875.00 | -62.7 Thousand | -18.98 Thousand | 18.48 Thousand | 11.42 Thousand | -415.19 Thousand |
| Inventory | -2.07 Million | - | 4.58 Million | -3.99 Million | 620.3 Thousand | - |
| Other working capital | -111.43 Thousand | -3.03 Million | -1579.00 | 3053.00 | 79.3 Thousand | 1.69 Million |
| Cash at beginning of period | 51.2 Thousand | 727.16 Thousand | - | 7855.00 | 8019.00 | 269.97 Thousand |
| Cash at end of period | 121.03 Thousand | 51.2 Thousand | 727.16 Thousand | - | 7855.00 | 8019.00 |
| Capital Expenditure | -3.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | -1.00 | - | - | - | 1.00 |
| Net cash flow / Change in cash | 69.83 Thousand | -675.95 Thousand | 727.16 Thousand | -7855.00 | -164.00 | -261.95 Thousand |
| Free Cash Flow | -173.92 Thousand | -606.92 Thousand | -1.13 Million | 18.64 Thousand | -481.79 Thousand | -1.57 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -117.1 Thousand | -122.47 Thousand | -349.76 Thousand | 1.15 Million | -325.02 Thousand | -99.21 Thousand |
| Depreciation & Amortization | 4339.00 | - | 4367.00 | 864.00 | 864.00 | - |
| Deferred income taxes | - | - | - | -255.14 Thousand | -250 Thousand | - |
| Stock-based compensation | - | - | - | 348.37 Thousand | 250 Thousand | - |
| Change in working capital | -49.13 Thousand | -91.18 Thousand | -21.79 Thousand | -1.92 Million | 50.75 Thousand | 12.21 Thousand |
| Other non-cash items | 21.45 Thousand | 4338.00 | 204.84 Thousand | 503.99 Thousand | 250 Thousand | -17.93 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | -1.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 156.32 Thousand | 162.93 Thousand | 165.79 Thousand | 243.75 Thousand | 143.75 Thousand | - |
| Debt repayment | -20.99 Thousand | -25 Thousand | -46.5 Thousand | -243.75 Thousand | -143.75 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 135.32 Thousand | 187.93 Thousand | 212.29 Thousand | 250 Thousand | 250 Thousand | - |
| Other Financing Activities | 156.32 Thousand | 162.93 Thousand | -46.5 Thousand | 237.5 Thousand | 37.5 Thousand | - |
| Accounts receivables | -27.42 Thousand | -27.42 Thousand | -12.29 Thousand | 254.27 Thousand | 56.54 Thousand | 22.57 Thousand |
| Accounts payables | -382.00 | -14.38 Thousand | 14.5 Thousand | 875.00 | 271.00 | -4644.00 |
| Inventory | - | - | 22.76 Thousand | -2.07 Million | 10.45 Thousand | 25.91 Thousand |
| Other working capital | -21.32 Thousand | -31.64 Thousand | -46.76 Thousand | -111.43 Thousand | -16.51 Thousand | -31.64 Thousand |
| Cash at beginning of period | 78.11 Thousand | 124.49 Thousand | 121.03 Thousand | 51.2 Thousand | 692.00 | 87.7 Thousand |
| Cash at end of period | 61.84 Thousand | 78.11 Thousand | 124.49 Thousand | 121.03 Thousand | 121.03 Thousand | 692.00 |
| Capital Expenditure | -1.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -16.26 Thousand | -46.38 Thousand | 3460.00 | 69.83 Thousand | 120.34 Thousand | -87 Thousand |
| Free Cash Flow | -172.59 Thousand | -209.32 Thousand | -162.33 Thousand | -173.91 Thousand | -23.4 Thousand | -87 Thousand |
SLI
TALBROSENG
2268
DJTWW
2405
ADH